We are live on
!
Find out more
SGH
Sivik Global Healthcare Portfolio holdings
AUM
$132M
1-Year Est. Return
24.1%
This Fund
S&P 500
This Quarter
Est. Return
+4.66%
1 Year Est. Return
+24.1%
3 Year Est. Return
+53.78%
5 Year Est. Return
+97.1%
10 Year Est. Return
+690.63%
AUM
$185M
AUM Growth
-$4.95M
(-2.6%)
Cap. Flow
-$7.94M
Cap. Flow
% of AUM
-4.29%
Top 10 Holdings %
Top 10 Hldgs %
49.31%
Holding
46
New
8
Increased
10
Reduced
9
Closed
15
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Intuitive Surgical
ISRG
|
+$7.74M |
| 2 |
Medtronic
MDT
|
+$6.71M |
| 3 |
Baxter International
BAX
|
+$5.72M |
| 4 |
AstraZeneca
AZN
|
+$5.06M |
| 5 |
State Street SPDR S&P Biotech ETF
XBI
|
+$4.47M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$5.24M |
| 2 |
Eli Lilly
LLY
|
+$4.99M |
| 3 |
AbbVie
ABBV
|
+$4.44M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$3.96M |
| 5 |
UnitedHealth
UNH
|
+$3.83M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 87.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Avantor
AVTR
$9.42B
| $3.24M | 1.75% |
200,000
| – | – |
|
27
Surgery Partners
SGRY
$2.01B
| $2.97M | 1.61% |
125,000
-75,000
| -38% | -$1.78M |
|
28
West Pharmaceutical
WST
$24.8B
| $2.8M | 1.51% |
+12,500
| New | +$3.45M |
|
|
29
UnitedHealth
UNH
$364B
| $2.62M | 1.42% |
5,000
-7,500
| -60% | -$3.83M |
|
30
PUT
Sarepta Therapeutics
SRPT
$1.94B
| $1.28M | 0.69% |
+20,000
| New | +$2.11M |
|
|
31
AbbVie
ABBV
$440B
| – | – |
-25,000
| Closed | -$4.44M |
|
32
Acadia Healthcare
ACHC
$2.95B
| – | – |
-50,000
| Closed | -$1.98M |
|
33
Alnylam Pharmaceuticals
ALNY
$30B
| – | – |
-7,000
| Closed | -$1.65M |
|
34
Bio-Rad Laboratories Class A
BIO
$9.68B
| – | – |
-10,000
| Closed | -$3.29M |
|
|
35
Bristol-Myers Squibb
BMY
$130B
| – | – |
-70,000
| Closed | -$3.96M |
|
36
BioNTech
BNTX
$23.3B
| – | – |
-15,000
| Closed | -$1.71M |
|
37
Edwards Lifesciences
EW
$53.6B
| – | – |
-50,000
| Closed | -$3.7M |
|
|
38
PUT
Intuitive Surgical
ISRG
$142B
| – | – |
-15,000
| Closed | -$7.83M |
|
39
PUT
Madrigal Pharmaceuticals
MDGL
$12.4B
| – | – |
-4,000
| Closed | -$1.23M |
|
40
Maravai LifeSciences
MRVI
$861M
| – | – |
-140,000
| Closed | -$763K |
|
41
Repligen
RGEN
$9.35B
| – | – |
-10,000
| Closed | -$1.44M |
|
|
42
Sarepta Therapeutics
SRPT
$1.94B
| – | – |
-10,000
| Closed | -$1.05M |
|
|
43
Vertex Pharmaceuticals
VRTX
$133B
| – | – |
-13,000
| Closed | -$5.24M |
|
44
Zimmer Biomet
ZBH
$18.7B
| – | – |
-20,000
| Closed | -$2.11M |
|
45
Zoetis
ZTS
$30.4B
| – | – |
-15,000
| Closed | -$2.44M |
|
Similar funds
AFP
PCGDR
ACM
9C
STFP
ADEF
AC
CIP
Sivik Global Healthcare's Q1 2025 Portfolio in Review
As of Q1 2025, Sivik Global Healthcare held 46 positions worth $185M, down 2.6% from $190M the previous quarter. Its ten largest holdings account for 49% of the portfolio.
Sivik Global Healthcare withdrew a net $7.94M in Q1 2025, closing 15 positions and reducing 9 holdings. Its most notable exit was Vertex Pharmaceuticals, an estimated $5.24M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 86% a quarter earlier.
Against the trend, Sivik Global Healthcare opened a new position in Intuitive Surgical worth $6.93M.
- Sivik Global Healthcare's largest Q1 2025 buy was Intuitive Surgical: 14,000 shares worth $6.93M.
- Sivik Global Healthcare added most to State Street SPDR S&P Biotech ETF in Q1 2025, an estimated $4.47M increase.
- Sivik Global Healthcare's biggest Q1 2025 reduction was Eli Lilly, cutting an estimated $4.99M.
- Sivik Global Healthcare fully exited Vertex Pharmaceuticals in Q1 2025, selling an estimated $5.24M.
- Sivik Global Healthcare's ten largest holdings make up 49% of its $185M portfolio in Q1 2025.
- Sivik Global Healthcare opened 8 new positions and closed 15 in Q1 2025.
- Sivik Global Healthcare's portfolio value fell 2.6% quarter-over-quarter to $185M.
Based on Sivik Global Healthcare's 13F filing for Q1 2025, filed 22 Apr 2025.